Company: INKT
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0000950170-25-055881
Chunk: 19

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 19
---
 Committee has postponed the review of annual incentive bonuses for 2024, and we have not yet determined the annual incentive bonuses, if any, that will be payable to our named executive officers. We expect that bonus amounts for 2024 will be determined in June 2025. For 2023, the amounts reported reflect the amount of the annual incentive bonus that would have been paid in cash, absent the Board's decision to issue payment in the form of options to purchase Company stock with the number of shares underlying such option determined by dividing 125% of the amount of the annual incentive bonus reported in the table by the closing price of our stock on the grant date ($8.70 per share, which was the closing price of our stock on January 16, 2024), which resulted in Drs. Buell and van Dijk being granted 66,091 and 17,107 options, respectively. As of the award date, the values of such grants, calculated in accordance with FASB ASC Topic 718, disregarding the effects of estimated forfeitures, were $456,034 and $118,044 for Drs. Buell and van Dijk, respectively. The grant date fair value of these incremental options is not included in the option awards column for 2023 because the options were granted in 2024. For Dr. Buell, the grant date fair value of this option is also not included in the option awards column for 2024 because the grant date fair value of the option award was less than the amount of the annual incentive bonus reported in the table. For Dr. van Dijk, the incremental grant date fair value of the option award in excess of the amount of the annual incentive bonus reported in the table is included in the option awards column for 2024. On January 9, 2023, Drs. Buell and van Dijk were granted shares of Company stock in respect of their 2022 annual incentive bonus having a value on the date of grant equal to 150% of the amount of the annual incentive bonus that was included in the Summary Compensation Table for 2022, based on the closing price of Company stock of $23.20 on the date of grant, which resulted in Drs. Buell and van Dijk being granted 24,784 and 5,162, respectively, shares of fully vested Company stock. The grant date fair value of the incremental shares was not included in the stock awards column for 2022 because the shares were